Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

CAR-T Therapy Versus Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: Systematic Review and Metanalysis of Toxicity and Response

Mansi Mehta, Devang Namjoshi, Bolivia Crocete Aloysia Fernandes, Vaibhavi Mukhtiar, Charmi Bhanushali, Madhan Srinivasan Kumar, Gunjan Rana, Jaison Lawrence Alexander Santhi, Tanisha Mishra, Muthalagu Ramanathan

Blood (2024) 144 (Supplement 1): 6929.

https://doi.org/10.1182/blood-2024-206207

Published: 2024

Journal Articles

Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations

Maria Rita Khouri, Bofei Wang, Poorva Bindal, Sakiko Suzuki, Lloyd Hutchinson, Laurie K Pearson, Andrew Gillis-Smith, Jan Cerny, Muthalagu Ramanathan, Jonathan M. Gerber, Shyam Ajay Patel

Blood (2024) 144 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2024-201680

Published: 2024

Journal Articles

Frameshift Mutations in Leukemia Associated Genes Correlate with Superior Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant for De Novo Acute Myeloid Leukemia Compared to Other Types of Mutations

Emma Camman, Sindha Madhav, Lloyd Hutchinson, Muthalagu Ramanathan, Jan Cerny, Jacob Bledsoe, Bruce Woda, Shyam Ajay Patel, William Selove

Blood (2023) 142 (Supplement 1): 6030.

https://doi.org/10.1182/blood-2023-177744

Published: 2023

Journal Articles

Myeloid Derived Suppressor Cells and Their Potential Impact on Minimal Residual Disease Status and Disease Response in a Cohort of Patients with Plasma Cell Dyscrasias

Andrew Wilks, Mohammed Wazir, Jonathan M. Gerber, Michael Brehm, Muthalagu Ramanathan

Blood (2023) 142 (Supplement 1): 6591.

https://doi.org/10.1182/blood-2023-190611

Published: 2023

Journal Articles

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Nina Caculitan, Josephine M. Cardarelli, Jack Khouri, Hyung C Suh, Muthalagu Ramanathan, Ann Woolfrey

Blood (2023) 142 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2023-187191

Published: 2023

Journal Articles

Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics

Shyam A Patel, William K Gerber, Lloyd Hutchinson, Shrinkhala Khanna, Jan Cerny, Muthalagu Ramanathan, Andrew Gillis-Smith, Sakiko Suzuki, Gregory A. Abel, Salwa Khedr, William Selove, Bruce Woda, Rena Zheng, Patricia Minehart Miron, Anne Higgins, Jonathan M Gerber

Blood (2022) 140 (Supplement 1): 5756–5758.

https://doi.org/10.1182/blood-2022-168473

Published: 2022

Journal Articles

Prognostic Discrimination within a Heterogeneous Population of TP53 -Aberrant Myelodysplastic Syndromes and Acute Myeloid Leukemia

Shyam A Patel, Jan Cerny, William K Gerber, Andrew Gillis-Smith, Muthalagu Ramanathan, Sakiko Suzuki, Lloyd Hutchinson, Anne Higgins, Patricia Minehart Miron, Ryan Horgan, Andrea Milano, Christie Perron, Rachel Pransky, Lindsey Shanahan, Karl Simin, Alyssa Tonelli, Jonathan M Gerber

Blood (2022) 140 (Supplement 1): 6276–6278.

https://doi.org/10.1182/blood-2022-168359

Published: 2022

Journal Articles

Impaired Clearance of DNMT3A/TET2/ASXL1 -Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia

Shyam A Patel, William K Gerber, Lloyd Hutchinson, Jan Cerny, Muthalagu Ramanathan, Andrew Gillis-Smith, Sakiko Suzuki, Salwa Khedr, Bruce Woda, William Selove, Jonathan M Gerber

Blood (2022) 140 (Supplement 1): 9150–9151.

https://doi.org/10.1182/blood-2022-169644

Published: 2022

Journal Articles

The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study

Muthalagu Ramanathan, Bipin B. Savani, Naya He, Soyoung Kim, Min Chen, Roy Chemaly, Christopher E Dandoy, Miguel-Angel Perales, Marcie L. Riches, Celalettin Ustun

Blood (2021) 138 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2021-145774

Published: 2021

Journal Articles

High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia

Neeraj Y Saini, MD, Jan Cerny, MD PhD, Vanessa Furtado, MD, Angela Desmond, Zheng Zhou, Glen D. Raffel, MD, Imran Puthawala, Jayde Bednarik, PharmD, Lindsey Shanahan, Patricia Minehart Miron, PhD, Bruce Woda, MD, Muthalagu Ramanathan, MD, Rajneesh Nath, MD

Blood (2018) 132 (Supplement 1): 1430.

https://doi.org/10.1182/blood-2018-99-116857

Published: 2018

Journal Articles

Hematopoeitic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia Patients

Neeraj Y Saini, MD, Jan Cerny, MD PhD, Vanessa Furtado, MD, Imran Puthawala, Angela Desmond, Muthalagu Ramanathan, MD, Rajneesh Nath, MD

Blood (2018) 132 (Supplement 1): 1396.

https://doi.org/10.1182/blood-2018-99-112639

Published: 2018

Journal Articles

Outcomes of Allogeneic Stem Cell Transplant (Allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in Patients Older Than 75 Years: A Single Center Analysis

Rajneesh Nath, MD, Jan Cerny, MD PhD, Muthalagu Ramanathan, MD, Zheng Zhou, MD PhD, Neng Yu, MD, Glen D Raffel, MD PhD, Jayde Bednarik, PharmD

Blood (2016) 128 (22): 5875.

https://doi.org/10.1182/blood.V128.22.5875.5875

Published: 2016

Journal Articles

Stratification of Allogeneic Hematopoietic Cell Transplant By Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Christopher Strouse, MD, Ying Zhang, Mei-Jie Zhang, PhD, Alyssa DiGilio, MS, Marcelo C. Pasquini, MD, Mary M. Horowitz, MD MS, Stephanie J. Lee, MD, Muthalagu Ramanathan, MD, Wichai Chinratanalab, MD, Alison W Loren, MD MS, Linda J. Burns, MD, Andrew Artz, MD, Kathleen F. Villa, MS, Wael Saber, MD MS

Blood (2016) 128 (22): 983.

https://doi.org/10.1182/blood.V128.22.983.983

Published: 2016

Journal Articles

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Blood (2016) 127 (20): 2427–2438.

https://doi.org/10.1182/blood-2015-11-679639

Published: 2016

Includes: Supplemental data

Journal Articles

Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis

Muthalagu Ramanathan, MD, Pierre Teira, MD MS, Minoo Battiwalla, MDMS, A. John Barrett, MD FRCP, FRCPath, Caroline A Lindemans, MD PhD, Jeffery Auletta, MD, Kwang Woo Ahn, PhD, Min Chen, PhD, Marcie L Riches, MD MS, Michael Boeckh, MD

Blood (2014) 124 (21): 47.

https://doi.org/10.1182/blood.V124.21.47.47

Published: 2014

Journal Articles

Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG)

Rajneesh Nath, MD, Muthalagu Ramanathan, MD, Jan Cerny, MD PhD, Zheng Zhou, MD PhD, Glen D Raffel, MD PhD, Jayde Bednarik, Pharm D, Neng Yu, MD, Laura J Petrillo-Deluca, PA-C, Zeina Al-Mansour, MD, Zankar Desai

Blood (2014) 124 (21): 1152.

https://doi.org/10.1182/blood.V124.21.1152.1152

Published: 2014

Journal Articles

High Dose Cyclophosphamide (HDCy) Post Stem Cell Transplant (SCT) Following High Dose Melphalan (HDMel) Based Conditioning As a Dual Strategy For Chemotherapy Dose Intensity and Graft Versus Host Disease (gvhd) Prophylaxis In Matched and Mismatched allogeneic (allo) SCT

Rajneesh Nath, MD, Jan Cerny, MD, Ph.D, Muthalagu Ramanathan, MD, Glen D Raffel, M.D, Ph.D., Jayde Bednarik, Pharm D, Neng Yu, MD, Zankar Desai, Lindsey Shanahan, PA-C, Natasha Fortier, PA-C, Mridula George, MD, Aimee Kroll-Desrosiers, MS

Blood (2013) 122 (21): 4554.

https://doi.org/10.1182/blood.V122.21.4554.4554

Published: 2013

Journal Articles

Optimizing Lentiviral Transduction of Human Natural Killer Cells

Su Su, MD, PhD, Dawn M Betters, Ph.D, Muthalagu Ramanathan, MD, Keyvan Keyvanfar, BS, Aleah Smith, Xingmin Feng, PhD, Elissa Furutani, Mattias Carlsten, MD Ph.D, Andreas Lundqvist, PhD, Richard Childs, MD

Blood (2011) 118 (21): 4714.

https://doi.org/10.1182/blood.V118.21.4714.4714

Published: 2011

Journal Articles

Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1 st Complete Remission (CR): A Single Institution Experience

Amanpreet Buttar, MD, Deepa Jagadeesh, MD, MPH, Jan Cerny, MD, PhD, Muthalagu Ramanathan, MD, Zheng Zhou, MD, PhD, Laura Petrillo-Deluca, PAC, Natasha Tarrasky, PAC, Jayde Bednarik, Pharm D, Zankar Desai, William V Walsh, MD, Rajneesh Nath, MD

Blood (2011) 118 (21): 4505.

https://doi.org/10.1182/blood.V118.21.4505.4505

Published: 2011

Journal Articles

Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT),

Jan Cerny, MD, PhD, Lesley Woods, MD, Hongbo Yu, MD, PhD, Muthalagu Ramanathan, MD, Glen D Raffel, M.D, Ph.D., William V Walsh, MD, Laura J Petrillo-Deluca, PA-C, Natasha M Tarrasky, PA-C, Elizabeth O'Rourke, NP, Jayde L Bednarik, PharmD, Bruce Woda, MD, Lloyd Hutchinson, PhD, Aimee Kroll, MS, Bruce Barton, PhD, Alan G. Rosmarin, MD, Rajneesh Nath, MD

Blood (2011) 118 (21): 3560.

https://doi.org/10.1182/blood.V118.21.3560.3560

Published: 2011

NARROW

CAR-T Therapy Versus Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: Systematic Review and Metanalysis of Toxicity and Response

Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations

Frameshift Mutations in Leukemia Associated Genes Correlate with Superior Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant for De Novo Acute Myeloid Leukemia Compared to Other Types of Mutations

Myeloid Derived Suppressor Cells and Their Potential Impact on Minimal Residual Disease Status and Disease Response in a Cohort of Patients with Plasma Cell Dyscrasias

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics

Prognostic Discrimination within a Heterogeneous Population of TP53 -Aberrant Myelodysplastic Syndromes and Acute Myeloid Leukemia

Impaired Clearance of DNMT3A/TET2/ASXL1 -Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia

The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study

High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia

Hematopoeitic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia Patients

Outcomes of Allogeneic Stem Cell Transplant (Allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in Patients Older Than 75 Years: A Single Center Analysis

Stratification of Allogeneic Hematopoietic Cell Transplant By Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis

Unrelated Donor (UD) Cord Blood (CB) Stem Cell Transplantation (SCT) from a Single CB Unit in Older Adults: Excellent Engraftment and Low Early Mortality with a Preparative Regimen of Melphalan (M), Thiotepa (T), Fludarabine(F), and Rabbit (r) Anti Thymocyte Globulin (ATG)

High Dose Cyclophosphamide (HDCy) Post Stem Cell Transplant (SCT) Following High Dose Melphalan (HDMel) Based Conditioning As a Dual Strategy For Chemotherapy Dose Intensity and Graft Versus Host Disease (gvhd) Prophylaxis In Matched and Mismatched allogeneic (allo) SCT

Optimizing Lentiviral Transduction of Human Natural Killer Cells

Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1 st Complete Remission (CR): A Single Institution Experience

Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only